Adding MSM Does Not Give Joint Supplements ACR Approval

The 2026 American College of Rheumatology (ACR) osteoarthritis summary strongly recommends against glucosamine, chondroitin, and glucosamine–chondroitin combinations for knee, hip and hand osteoarthritis. MSM is not named in the published recommendation summary. Adding MSM therefore does not give a glucosamine–chondroitin blend an ACR endorsement—but the summary also does not issue a specific recommendation against MSM itself. Read the official 2026 summary.

For a three-ingredient joint supplement, the distinction is straightforward: the glucosamine–chondroitin base is discouraged by this guideline, while MSM and the exact triple formula need their own evidence assessment.

Choose the ingredients on your label to see what the recommendation covers.

The Recommendation Covers Knee, Hip and Hand Osteoarthritis

The ACR’s wording is:

“In people with knee, hip, and hand OA, we strongly recommend against glucosamine, chondroitin, and combination preparations of glucosamine and chondroitin.”

The summary labels the recommendation strong, with evidence certainty described as low for glucosamine alone and moderate for the combination. Recommendation strength and evidence certainty are different judgments: “strong” does not mean every supporting study is high quality.

The ACR’s guideline page lists the 2026 summary. The summary states that it was approved by the ACR Board of Directors and that a full manuscript will be submitted for journal publication. It provides the recommendation and evidence ratings, not a detailed supplement-specific explanation of the new decision.

These recommendations concern osteoarthritis, not rheumatoid arthritis or every cause of joint pain. They guide treatment decisions rather than ban products or replace individualized care.

The Hand-OA Chondroitin Exception Is Gone

Glucosamine–chondroitin was not newly rejected for knee OA in 2026. Much of the advice was already negative in 2019.

Preparation	2019 Guidance	2026 Summary
Glucosamine	Strongly against: knee, hip, hand	Strongly against: all three
Chondroitin sulfate	Strongly against: knee, hip; conditionally for: hand	Strongly against: all three
Glucosamine–chondroitin	Strongly against: knee, hip	Strongly against: knee, hip, hand

The comparison comes from the 2019 ACR/Arthritis Foundation guideline and the 2026 summary linked above. The clearest reversal is chondroitin for hand OA: the older conditional recommendation in favor no longer applies under the updated guidance.

The 2019 panel explained that glucosamine studies with the lowest risk of bias failed to show important benefits over placebo. That is the older panel’s rationale—not a substitute for the forthcoming 2026 manuscript’s explanation.

The Triple Combination Has Limited Direct Trial Evidence

There is direct research on glucosamine–chondroitin–MSM, so the formula should not be dismissed as completely unstudied. But evidence of a possible benefit is not the same as an ACR recommendation.

A 2017 double-blind randomized trial by Lubis and colleagues enrolled 147 people with early radiographic knee OA, Kellgren–Lawrence grades I–II. Over 12 weeks, it compared placebo with two supplement preparations:

Daily Ingredient	Glucosamine–Chondroitin	Triple Combination
Glucosamine	1,500 mg	1,500 mg
Chondroitin sulfate	1,200 mg	1,200 mg
MSM	Not included	500 mg

Researchers assessed pain on a visual analogue scale and pain, stiffness and physical function using the WOMAC questionnaire. They reported results favoring the MSM-containing combination, particularly for pain at week 12.

That is a positive short-term signal, not proof that adding MSM reliably makes the combination effective. Baseline WOMAC scores differed between groups, which the authors acknowledged could bias comparisons. The abstract and methods also reverse the MSM-combination and placebo group counts.

The trial had no MSM-only arm, so it cannot establish whether glucosamine and chondroitin were necessary. Its participants had early knee OA; it does not establish benefit for hip or hand OA. Symptom outcomes also do not demonstrate cartilage rebuilding or long-term disease modification.

MSM Alone Is Not a Proven Workaround

A 2011 placebo-controlled knee-OA study assigned 50 participants to 3.375 g MSM daily or placebo for 12 weeks. In the adjusted analysis, physical function and total WOMAC scores favored MSM, but WOMAC pain did not differ significantly.

The authors described the improvements as small, with uncertain clinical importance. The study also used alternating allocation by enrollment order and had baseline differences between groups, further limiting confidence.

The 500 mg MSM dose in the triple-combination trial and the 3.375 g dose in the MSM-only study are study doses, not recommended regimens. These studies do not establish that switching from a blend to plain MSM will improve symptoms, or that increasing the MSM content of a blend will overcome the guideline’s recommendation.

For the broader formulation comparison, see Does Glucosamine Chondroitin MSM Work for Joint Pain?.

An Existing Supplement Deserves a Benefit and Safety Review

Use the update as a reason to review the product—not to replace it automatically with plain MSM.

Bring the full label and medication list to your clinician or pharmacist. The useful questions are specific: whether the supplement has meaningfully improved an activity that matters to you, whether its ongoing cost is justified, and whether it is displacing better-supported care.

The ACR recommends exercise for knee and hip OA, weight loss when overweight or obesity is present, and appropriate medication options, including topical NSAIDs for knee and hand OA. Treatment still needs to account for individual risks and preferences; the official summary linked above sets out those recommendations.

Safety needs a separate assessment. Glucosamine and chondroitin have been associated with increased bleeding risk in people taking warfarin, and glucosamine may raise blood glucose in some people, according to NCCIH. Those cautions concern the ingredients in the blend, regardless of whether MSM is added.

The guideline does not support buying a glucosamine–chondroitin–MSM supplement on the assumption that its extra ingredient rescues the base combination. Trying or continuing it should rest on the formula’s limited evidence, personal safety considerations and a clear assessment of benefit—not implied ACR approval.